Phase Ib/II Study of QL1706 + Fruquintinib + SCRT vs. Standard Third-Line Therapy in Unresectable Liver-Metastatic pMMR/MSS Colorectal Cancer: Safety, Tolerability, and Efficacy.
PHASE2
This study is designed to evaluate the safety, tolerability, and efficacy o...
Status
Not Yet Recruiting
Location
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial
PHASE2
The primary objective of this study is to evaluate whether neoadjuvant SBRT...